Lafutidine 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial

Table 2

Proportion of patients achieving symptom relief (GOS ≤ 2), symptom resolution (GOS = 1), and symptom improvement (ΔGOS ≥ 2).

		Lafutidine (𝑁=99) 𝑁 (%) (95% CI)	Rabeprazole (𝑁=95) 𝑁 (%) (95% CI)	Difference (95% CI)	𝑃 value
Symptom relief (GOS ≤ 2)	Week 2	15 (15.15) (8.74 to 23.76)	13 (13.68) (7.49 to 22.26)	1.50% (−9.40 to 12.40)	.840
	Week 4	89 (89.90) (82.21 to 95.05)	62 (65.26) (54.80 to 74.74)	24.60% (12.30 to 36.90)	<.001
Symptom resolution (GOS = 1)	Week 2	1 (1.01) (0.03 to 5.50)	5 (5.26) (1.73 to 11.86)	−4.30% (−10.20 to 1.70)	.113
	Week 4	70 (70.71) (60.71 to 79.43)	24 (25.26) (16.91 to 35.22)	45.40% (31.90 to 59.00)	<.001
Symptom improvement (ΔGOS ≥ 2)	Week 2	65 (65.66) (55.44 to 74.91)	51 (53.68) (43.15 to 63.98)	12.00% (−2.80 to 26.70)	.107
	Week 4	91 (91.92) (84.70 to 96.45)	85 (89.47) (81.49 to 94.84)	2.40% (−6.80 to 11.70)	.626